AI Blood Test Detects 32 Cancers
New Delhi: Gurugram-based startup Predomics has recently developed an AI-based blood test that can detect 32 types of cancer in men and women with an accuracy rate of 98 percent. The innovative test, which combines artificial intelligence with the company’s patented technology, OncoVerix-F, identifies metabolite signatures of multiple cancers in a single test.
According to Dr. Kanuri VS, the co-founder and chief scientific officer of PredOmics, metabolomics is a suitable technique for cancer detection. The test was initially launched in 2022 to detect breast, endometrium, cervix, and ovary cancers in women with a single blood test. After the success of the initial test, the company expanded it to detect 32 types of cancer in both men and women.
The blood test can detect a range of cancers, including breast cancer, stomach cancer, oral cancer, liver cancer, brain cancer, and sarcoma. This breakthrough in cancer detection could potentially save millions of lives worldwide by detecting cancer at an early stage, allowing for more effective treatment options.
The development of this innovative blood test is significant, as cancer remains a leading cause of death worldwide. According to the World Health Organization (WHO), cancer accounts for approximately 9.6 million deaths per year globally. With this new technology, there is hope for earlier detection and better outcomes for cancer patients.
The Predomics blood test has the potential to revolutionize cancer detection and make a significant impact in the fight against cancer. The company plans to make the test available to hospitals and clinics globally, with the aim of improving cancer detection rates and ultimately saving lives.